Investigating the effect of topical products containing postbiotics and indigenous probiotic strains of Iran on eczema symptoms

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20251230068491N1

Enrollment

Registered

2026-04-04

Start date

2026-10-23

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

eczema. Atopic dermatitis

Interventions

Intervention 1: Intervention group: In the intervention group, patients with eczema will receive a topical product containing a complex of postbiotics and indigenous probiotic strains of Iran. Partici

Eligibility

Sex/Gender

All

Age

12 Years to No maximum

Inclusion criteria

Inclusion criteria: Age = 12 years Confirmed diagnosis of eczema by a dermatologist Stable disease for at least 3 months No use of similar medications within 2 weeks prior to enrollment Providing informed consent to participate in the study

Exclusion criteria

Exclusion criteria: Age under 12 years Pregnancy or breastfeeding History of hypersensitivity to the components of probiotic or postbiotic-containing products Presence of skin infection or malignancy at the treatment site Unwillingness to participate in the study

Design outcomes

Primary

Measure	Time frame
Change in the severity and extent of eczema lesions based on the SCORAD (Scoring Atopic Dermatitis) index in patients with eczema. This index evaluates the extent of skin involvement, clinical severity including erythema, edema, scaling, excoriation, lichenification, and subjective symptoms including pruritus and sleep disturbance. SCORAD scores will be measured before the intervention and during the one-month treatment follow-up period (weekly assessments) and compared between groups. Timepoint: Before intervention (Baseline) and at the end of the one-month treatment period. Method of measurement: The severity and extent of eczema will be assessed using the standardized SCORAD index by a dermatologist.	—

Measure

Time frame

Change in the severity and extent of eczema lesions based on the SCORAD (Scoring Atopic Dermatitis) index in patients with eczema. This index evaluates the extent of skin involvement, clinical severity including erythema, edema, scaling, excoriation, lichenification, and subjective symptoms including pruritus and sleep disturbance. SCORAD scores will be measured before the intervention and during the one-month treatment follow-up period (weekly assessments) and compared between groups. Timepoint: Before intervention (Baseline) and at the end of the one-month treatment period. Method of measurement: The severity and extent of eczema will be assessed using the standardized SCORAD index by a dermatologist.

—

Secondary

Measure	Time frame
Assessment of eczema symptom severity from the patient’s perspective using the validated Patient-Oriented Eczema Measure (POEM) questionnaire. This tool evaluates the frequency of eczema symptoms including itching, sleep disturbance, skin dryness, flaking, cracking, oozing, and bleeding during the previous week. Timepoint: Before intervention (Baseline) and at the end of the one-month treatment period. Method of measurement: Eczema symptom severity will be measured using the POEM( Patient-Oriented Eczema Measure) questionnaire completed by the patient.;Assessment of quality of life in patients with eczema using the validated Dermatology Life Quality Index (DLQI) questionnaire. This tool evaluates the impact of skin disease on different aspects of daily life including symptoms and feelings, daily activities, social activities, work and school, personal relationships, and treatment. Timepoint: Before intervention (Baseline) and at the end of the one-month treatment period. Method of measurement: Quality of life will be assessed using the DLQI( Dermatology Life Quality Index) questionnaire completed by the patient.	—

Measure

Time frame

Assessment of eczema symptom severity from the patient’s perspective using the validated Patient-Oriented Eczema Measure (POEM) questionnaire. This tool evaluates the frequency of eczema symptoms including itching, sleep disturbance, skin dryness, flaking, cracking, oozing, and bleeding during the previous week. Timepoint: Before intervention (Baseline) and at the end of the one-month treatment period. Method of measurement: Eczema symptom severity will be measured using the POEM( Patient-Oriented Eczema Measure) questionnaire completed by the patient.;Assessment of quality of life in patients with eczema using the validated Dermatology Life Quality Index (DLQI) questionnaire. This tool evaluates the impact of skin disease on different aspects of daily life including symptoms and feelings, daily activities, social activities, work and school, personal relationships, and treatment. Timepoint: Before intervention (Baseline) and at the end of the one-month treatment period. Method of measurement: Quality of life will be assessed using the DLQI( Dermatology Life Quality Index) questionnaire completed by the patient.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehdi Rajabi

Islamic Azad University

mehdirj@aol.co.uk+98 21 2264 0052

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026